Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct 13;9(4):147.
doi: 10.3390/diagnostics9040147.

Ocular Surface Workup in Patients with Meibomian Gland Dysfunction Treated with Intense Regulated Pulsed Light

Luca Vigo  1 , Leonardo Taroni  2 , Federico Bernabei  3 , Marco Pellegrini  4 , Stefano Sebastiani  5 , Andrea Mercanti  6 , Nicola Di Stefano  7 , Vincenzo Scorcia  8 , Francesco Carones  9 , Giuseppe Giannaccare  10
Affiliations

Ocular Surface Workup in Patients with Meibomian Gland Dysfunction Treated with Intense Regulated Pulsed Light

Luca Vigo et al. Diagnostics (Basel). .

Abstract

The purpose of the present study was to evaluate changes of signs and symptoms in patients with meibomian gland dysfunction (MGD) treated with intense regulated pulsed light (IRPL), and to further investigate which parameter could predict positive outcomes of the procedure. Twenty-eight patients who bilaterally received three IRPL sessions at day 1, 15, and 45 satisfied the criteria and were included in the study. Non-invasive break-up time (NIBUT), lipid layer thickness (LLT), meibography, tear osmolarity, and ocular discomfort symptoms were measured before and 30 days after the last IRPL session. Qualified or complete success was defined in the presence of an improvement of symptoms associated with an increase of NIBUT (< or ≥ 20%). After IRPL treatment, median NIBUT and LLT increased from 7.5 to 10.2 s and 2.0 to 3.0, respectively (p <0.001); tear osmolarity decreased from 304.0 to 301.0 mOsm/L (p = 0.002). Subjective symptoms improved after IRPL in 26 patients. Qualified success was reached in 34 eyes, while complete success in 16 eyes. Patients with lower baseline break-up time (BUT) values showed better response to treatment (p = 0.04). In conclusion, IRPL improved signs and symptoms in MGD patients, while lower baseline NIBUT values were predictive of better response to IRPL.

Keywords: dry eye disease; evaporative dry eye; intense pulsed light; meibomian gland disease; non-invasive break-up time.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. All the authors read and approved the submitted version.

Figures

Figure 1
Figure 1
Box-plot analysis of non-invasive break-up time (NIBUT) (part A), lipid layer thickness grade (part B), meibomian gland loss (part C) and tear osmolarity (part D) before and 30 days after the last session of intense regulated pulsed light treatment.
Figure 2
Figure 2
Distribution of patients according to the 5-grade scale about their perceived improvement in symptoms after intense regulated pulsed light treatment.
Figure 3
Figure 3
Box-plot analysis of baseline non-invasive break-up time in patients belonging to the success group and in the others.
Figure 4
Figure 4
Linear regression analysis between baseline value and delta (Δ) value for non-invasive break-up time (part A), tear osmolarity (part B), and meibomian gland loss (part C).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Craig J.P., Nichols K.K., Akpek E.K., Caffery B., Dua H.S., Joo C.K., Liu Z., Nelson J.D., Nichols J.J., Tsubota K., et al. TFOS DEWS II Definition and Classification Report. Ocul Surf. 2017;15:276–283. doi: 10.1016/j.jtos.2017.05.008. - DOI - PubMed
    1. Uchino M., Uchino Y., Dogru M., Kawashima M., Yokoi N., Komuro A., Sonomura Y., Kato H., Kinoshita S., Schaumberg D.A., et al. Dry eye disease and work productivity loss in visual display users: The Osaka study. Am. J. Ophthalmol. 2014;157:294–300. doi: 10.1016/j.ajo.2013.10.014. - DOI - PubMed
    1. Sato E.A., Matsumoto Y., Dogru M., Kaido M., Wakamatsu T., Ibrahim O.M., Obata H., Tsubota K. Lacrimal gland in Sjogren’s syndrome. Ophthalmology. 2010;117:1055. doi: 10.1016/j.ophtha.2009.11.034. - DOI - PubMed
    1. Versura P., Giannaccare G., Pellegrini M., Sebastiani S., Campos E.C. Neurotrophic keratitis: Current challenges and future prospects. Eye Brain. 2018;10:37–45. doi: 10.2147/EB.S117261. - DOI - PMC - PubMed
    1. Giannaccare G., Bonifazi F., Sessa M., Fresina M., Arpinati M., Bandini G., Versura P. Dry eye is already present in haematological patients before hematopoietic stem cell transplantation. Cornea. 2016;35:638–643. doi: 10.1097/ICO.0000000000000747. - DOI - PubMed

LinkOut - more resources